| BDIV |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
male |
200 days
| 63 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
|
98155 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
female |
200 days
| 49 |
10.0 |
% |
0.46 |
3.25 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98146 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
female |
200 days
| 47 |
26.0 |
% |
0.69 |
4.75 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98149 |
2018 |
| BDIV |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
female |
200 days
| 49 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
|
98156 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 100 |
76.0 |
% |
0.45 |
4.5 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98163 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
female |
200 days
| 47 |
74.0 |
% |
0.69 |
4.75 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98165 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 86 |
75.0 |
% |
0.46 |
4.25 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98166 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
male |
200 days
| 56 |
75.0 |
% |
0.8 |
6.0 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98168 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
female |
200 days
| 62 |
74.0 |
% |
0.73 |
5.75 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98169 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
male |
200 days
| 39 |
22.0 |
% |
1.12 |
7.0 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98148 |
2018 |
| BDIX |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
female |
200 days
| 52 |
41.0 |
% |
1.07 |
7.75 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98143 |
2018 |
| BDIX.BDIV-D6Rat132-D6Rat229/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 24 |
19.0 |
% |
1.74 |
8.5 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98151 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
male |
200 days
| 56 |
25.0 |
% |
0.8 |
6.0 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98152 |
2018 |
| BDIX |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
male |
200 days
| 57 |
45.0 |
% |
0.66 |
5.0 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98158 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
male |
200 days
| 51 |
62.0 |
% |
1.05 |
7.5 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98161 |
2018 |
| BDIV |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
female |
200 days
| 49 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98172 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 100 |
24.0 |
% |
0.45 |
4.5 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98147 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 86 |
25.0 |
% |
0.46 |
4.25 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98150 |
2018 |
| BDIV |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 112 |
0.0 |
% |
|
|
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
|
98157 |
2018 |
| BDIX |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
female |
200 days
| 52 |
59.0 |
% |
1.07 |
7.75 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98159 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
female |
200 days
| 49 |
90.0 |
% |
0.64 |
4.5 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98162 |
2018 |
| BDIV |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
male |
200 days
| 63 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98171 |
2018 |
| BDIV |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 112 |
100.0 |
% |
|
|
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98173 |
2018 |
| BDIX |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
male |
200 days
| 57 |
55.0 |
% |
0.89 |
6.75 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98142 |
2018 |
| BDIX |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 109 |
49.0 |
% |
0.48 |
5.0 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98144 |
2018 |
| BDIX.BDIV-D6Mit1-D6Mgh2/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
male |
200 days
| 51 |
38.0 |
% |
1.05 |
7.5 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98145 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
female |
200 days
| 62 |
26.0 |
% |
0.73 |
5.75 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98153 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
percentage of study population displaying trigeminal nerve neurilemmomas at a point in time |
N-ethyl-N-nitrosourea (80 ug/g) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
trigeminal nerve integrity trait |
both |
200 days
| 118 |
25.0 |
% |
0.37 |
4.0 |
in vivo visual assessment |
0.0 |
|
0 |
|
inferred from Kaplan-Meier plot analysis |
SD approximated from 95%CI |
98154 |
2018 |
| BDIX |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 109 |
51.0 |
% |
0.48 |
5.0 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98160 |
2018 |
| BDIX.BDIV-D6Rat132-D6Mgh3/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
male |
200 days
| 39 |
78.0 |
% |
1.12 |
7.0 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98164 |
2018 |
| BDIX.BDIV-D6Rat132-D6Rat229/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 24 |
80.0 |
% |
1.79 |
8.75 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98167 |
2018 |
| BDIX.BDIV-D6Mit8-D6Rat229/Zte |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time |
N-ethyl-N-nitrosourea (80 mg/kg) |
van den Berg L, et al., Int J Cancer. 2015 May 1;136(9):2099-108. doi: 10.1002/ijc.29256. Epub 2014 Oct 28. |
life span trait |
both |
200 days
| 118 |
75.0 |
% |
0.37 |
4.0 |
in vivo visual assessment |
0.0 |
ENU injection |
200 |
days |
PI time in S1 |
ratio of survivors of malignant peripheral nerve sheath tumors to total study population during a period of time (CMO:0003873) |
98170 |
2018 |
